Agreement covers high-throughput genetics analysis using Grid computing platform for rapid development and publication of applications for cancer research
InforSense reports that the National Cancer Institute (NCI), the US federal government's principal agency for cancer research, has chosen InforSense technology for high-throughput genetic data analysis in cancer research.
Investigators at the Core Genotyping Facility (CGF) of the NCI in Gaithersburg, USA, will use InforSense's workflow-based integrative analytics platform, InforSense KDE, for rapid application development for their own research and also plan to publish cutting-edge analysis methods via a web portal to the wider research community.
"Investigators require access to the latest analysis techniques to advance their research.
"Therefore, creating the informatics infrastructure to compose and deliver these methods is a high priority at the CGF," said Meredith Yeager, scientific director, Core Genotyping Facility, NCI.
"After an extensive review of the available commercial and open source options, we recognised that InforSense KDE is able to provide the functionality, flexibility, and scalability we need to support our research, and to develop Cabig (Cancer Biomedical Informatics Grid)-compatible applications".
"We are delighted that NCI has selected InforSense KDE for their genetics analysis platform," commented Yike Guo, CEO and founder of InforSense.
"InforSense KDE is designed to enable scientists to easily build and publish their analytical applications by accessing and integrating diverse data, methods and services available within a large organisation.
"The agreement with NCI underlines our commitment to establish InforSense KDE as the standard platform for application development within an informatics grid".
The US National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programmes with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
The Core Genotyping Facility has the goal of meeting the genotyping and DNA sequencing needs of the NCI's Division of Cancer Epidemiology and Genetics (DCEG) and Center for Cancer Research (CCR).
The facility performs high-throughput genotyping and sequencing to support genetic analysis for a broad range of projects for the intramural research program of the NCI.
The CGF is assessing human genetic variation, including single nucleotide polymorphisms (SNPs) and other types of genetic variation (such as microsatellites and insertion/deletion mutations), in a large number of population based and family studies initiated by NCI investigators.
InforSense claims to be the leader in integrative analytics, enabling organisations to orchestrate and optimise their business-critical decision-making processes.
It says that leading pharmaceutical and biotechnology companies, financial services companies, and research institutes are using the company's flagship product, InforSense KDE, to enhance productivity across life science R and D, healthcare and business analytics.
The company is privately held, with European headquarters in London, UK, and North American headquarters in Cambridge, Massachusetts.
Using InforSense KDE, enterprises rapidly integrate and deliver virtually any data source, analytic software tool, service or application within a single informatics framework.
Users link these components via visual workflows to dynamically answer any question using their data, however complex or transient.
Organisations can also mine their analytical processes to discover and deploy expertise and best practises.
InforSense KDE provides an open, extensible service-oriented architecture, built using industry standards including J2EE, XML, and WSDL.
The InforSense Oracle Edition is a state-of-the-art solution for enterprise wide integrative analytics using Oracle's advanced information management and processing capabilities.
